Search Result

Results for "

cancer immunotherapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Anaplastic lymphoma kinase (ALK) (1) Autophagy (1) Biochemical Assay Reagents (2) c-Kit (2) CD47 (1) CD73 (1) Checkpoint Kinase (Chk) (1) CTLA-4 (1) Discoidin Domain Receptor (2) Endogenous Metabolite (6) FLT3 (3) HDAC (1) IFNAR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (1) Interleukin Related (1) Ligands for Target Protein for PROTAC (1) MAP4K (2) PARP (1) PD-1/PD-L1 (6) Phosphatase (1) Prostaglandin Receptor (1) PROTACs (1) ROR (1) STING (8) TAM Receptor (1) Toll-like Receptor (TLR) (3) Trk Receptor (2) VEGFR (2)
By Research Areas:	Cancer (53) Inflammation/Immunology (17) Neurological Disease (1)

By Targets:

Adenosine Receptor (1)

Anaplastic lymphoma kinase (ALK) (1)

Autophagy (1)

Biochemical Assay Reagents (2)

c-Kit (2)

CD47 (1)

CD73 (1)

Checkpoint Kinase (Chk) (1)

CTLA-4 (1)

Discoidin Domain Receptor (2)

Endogenous Metabolite (6)

FLT3 (3)

HDAC (1)

IFNAR (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Integrin (1)

Interleukin Related (1)

Ligands for Target Protein for PROTAC (1)

MAP4K (2)

PARP (1)

PD-1/PD-L1 (6)

Phosphatase (1)

Prostaglandin Receptor (1)

PROTACs (1)

ROR (1)

STING (8)

TAM Receptor (1)

Toll-like Receptor (TLR) (3)

Trk Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (53)

Inflammation/Immunology (17)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-133123

EP4 receptor antagonist 1	Prostaglandin Receptor	Inflammation/Immunology Cancer
EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC₅₀s of 6.1 nM and 16.2 nM, respectively. IC₅₀s >10 μM for human EP1, EP2,and EP3 receptors .

HY-P99175

KWAR 23	CD47	Cancer
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .

HY-33299

Serpin B9-IN-1 BTCA	Biochemical Assay Reagents	Cancer
Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .

HY-146231A

SS47 TFA	MAP4K PROTACs	Inflammation/Immunology Cancer
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-164072

DBCO-Dextran	Biochemical Assay Reagents	Others Cancer
DBCO-Dextran is a dibenzocyclooctyne-modified dextran with excellent click chemistry activity and biocompatibility, which can be used in cancer immunotherapy and bioimaging research .

HY-149520

HPK1-IN-39	MAP4K	Cancer
HPK1-IN-39 (Compound 10n) is a selective HPK1 Inhibitor (IC₅₀: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy .

HY-155675

TPPC	Others	Cancer
TPPC, a porphyrin cholesterol conjugate, can render cancer cells more sensitive to ICIs. TPPC can enhance photodynamic immunotherapy toward lung cancer .

HY-153544

TLR7/8 agonist 9	Toll-like Receptor (TLR)	Cancer
TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC₅₀s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy .

HY-160151

TP1L	Ligands for Target Protein for PROTAC	Cancer
TP1L is a selective TC-PTP PROTAC degrader for *cancer* immunotherapy with a DC50 value of 35.8 nM .

HY-P9902

Pembrolizumab Maximum Cited Publications 14 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-N10116A

Calamenene	Others	Cancer
Calamenene is a major sesquiterpenoid, which could be isolated from Cupressus bakeri foliage. Calamenene affects the maturation and function of human monocyte-derived dendritic cells .

HY-144072

MRS4620	CD73	Inflammation/Immunology Cancer
MRS4620 is a potent CD73 inhibitor, with a K_i of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch .

HY-130607

IDO1-IN-2	Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology Cancer
IDO1-IN-2 (compound 16) is a potent and selective IDO1 inhibitor with IC₅₀s of 81 nM, 59 nM (mouse) and 28 nM (rat), respectively. IDO1-IN-2 has anti-cancer activity .

HY-N1420A

Rhamnose monohydrate L-Rhamnose monohydrate	Endogenous Metabolite	Cancer
Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies . Rhamnose monohydrate crosses the epithelia via the transcellular pathway and acts as a marker of intestinal absorption .

HY-N1420AR

Rhamnose monohydrate (Standard)	Endogenous Metabolite	Cancer
Rhamnose (monohydrate) (Standard) is the analytical standard of Rhamnose (monohydrate). This product is intended for research and analytical applications. Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies . Rhamnose monohydrate crosses the epithelia via the transcellular pathway and acts as a marker of intestinal absorption .

HY-108681

680C91 1 Publications Verification	Others	Neurological Disease Inflammation/Immunology Cancer
680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a K_i of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease .

HY-154919

DC-Y13-27 2 Publications Verification	Others	Cancer
DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 enhances tumor responses to radiotherapy and immunotherapy .

HY-162726

GCS-11	Interleukin Related	Cancer
GCS-11 is a powerful natural killer T (NKT) cell agonist. It boosts the production of IFN-γ and IL-4, with a particular selectivity for IFN-γ. GCS-11 exhibits anticancer activity. GCS-11 has the potential for research into cancer immunotherapies or vaccine development as a promising adjuvant .

HY-13735H

Quinacrine acetate Acriquine acetate	Others	Cancer
Quinacrine (Acriquine) acetate is a small molecule modulator of the cGAS-STING-TBK1 signaling pathway, possessing immune stimulatory activity. Quinacrine acetate has been explored for its potential therapeutic applications in enhancing anti-tumor immunity. Quinacrine acetate can improve the effectiveness of cancer immunotherapies by addressing the poor immunogenicity of various tumors. Quinacrine acetate also presents a promising strategy for overcoming the limitations associated with immune checkpoint inhibitors in cancer treatment.

HY-126321

RORγt agonist 1	ROR	Cancer
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC₅₀ of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy .

HY-111786

LHC-165	Toll-like Receptor (TLR)	Cancer
LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .

HY-155109

Antitumor agent-114	STING	Inflammation/Immunology Cancer
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research .

HY-143324

A2AAR/HDAC-IN-1	HDAC Adenosine Receptor	Cancer
A2AAR/HDAC-IN-1 (compound 14c) is an orally active, potent and balanced A_2AAR/HDAC dual inhibitor, with a K_i of 163.5 nM for A_2AAR and an IC₅₀ of 145.3 nM for HDAC1. A2AAR/HDAC-IN-1 shows anticancer activity .

HY-161518

PD-1/PD-L1-IN-44	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits PD-1/PD-L1 proteins (IC₅₀=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8 ⁺ cell infiltration .

HY-P10417

RTDLDSLRTYTL	Integrin	Others Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-163719

PARP7-IN-22	PARP	Cancer
PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC₅₀ of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy .

HY-119109

Laminaran	Others	Cancer
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities . Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds . Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy .

HY-132200

UNC5293	TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3	Cancer
UNC5293 is a MERTK-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC₅₀=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research .

HY-159894

Autophagy-lysosome activator-1	Autophagy	Cancer
Autophagy-lysosome activator-1 (Compound F1) is a Autophagy-lysosome activator. Autophagy-lysosome activator-1 effectively induces PD-L1 or VISTA degradation in tumor cells .

HY-116604

RLX PD 139530	Others	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

HY-155847

LYP-IN-3	Phosphatase	Cancer
LYP-IN-3 (compound D34) is a selective inhibitor of Lymphoid-tyrosine phosphatase (LYP) (Ki=0.93 μM), and regulates T-cell receptor (TCR) signaling pathway in tumor progress. LYP-IN-3 activates T-cell and inhibits M2 macrophage polarization, but upregulates PD-1/PD-L1 expression. LYP-IN-3 can be leveraged with PD-1/PD-L1 inhibitor, for futher cancer immunotherapy .

HY-107780

Cyclic-di-GMP c-di-GMP; cyclic diguanylate; 5GP-5GP	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research .

HY-107780A

Cyclic-di-GMP sodium c-di-GMP sodium; cyclic diguanylate sodium; 5GP-5GP sodium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research .

HY-107780B

Cyclic-di-GMP diammonium 5 Publications Verification c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .

HY-110382

Cyclic-di-GMP disodium 5 Publications Verification c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .

HY-P99809

Quavonlimab MK-1308	CTLA-4	Cancer
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .

HY-162874

diABZI-V/C-DBCO	STING	Inflammation/Immunology Cancer
diABZI-V/C-DBCO (Compound 3) is a potent STING agonist. diABZI-V/C-DBCO can release diABZI-amine upon activation by cathepsin B to activate STING, leading to the production of interferons and other immune-stimulatory molecules, thereby enhancing the immune system's response to tumors. The EC₅₀ values for diABZI-V/C-DBCO and diABZI-amine in activating STING in THP1-Dual cells are 1.47 and 0.144 nM, respectively, and in primary mouse splenocytes, the EC₅₀ values are 7.7 and 0.17 μM, respectively. diABZI-V/C-DBCO can be used in cancer immunotherapy research .

HY-144501

D18	Toll-like Receptor (TLR) PD-1/PD-L1	Inflammation/Immunology Cancer
D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC₅₀=24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 .

HY-P99032

Monalizumab 2 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

HY-144329

STING agonist-11	STING	Inflammation/Immunology Cancer
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea activator of STING with EC₅₀ of 18 nM. Activation of STING is a highly promising approach in immunotherapy .

HY-144328

STING agonist-10	STING	Inflammation/Immunology Cancer
STING agonist-10 (Compound 91) is a potent small molecule cyclic urea activator of STING with the EC₅₀ of 2600 nM. Activation of STING is a highly promising approach in immunotherapy .

HY-16961

Sitravatinib 3 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

Cat. No.	Product Name

HY-L079

Anti-Blood Cancer Compound Library

2,724 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2,724 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L075

Anti-Lung Cancer Compound Library

1,909 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1,909 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L031

Small Molecule Immuno-Oncology Compound Library

494 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 494 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Target	Research Area

HY-P3488

GADGVGKSA	Peptides	Inflammation/Immunology Cancer
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3486

GADGVGKSAL	Peptides	Inflammation/Immunology Cancer
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-P3485

GAGGVGKSAL	Peptides	Cancer
GAGGVGKSAL is a wild-type KRAS G12D 10mer peptide. GAGGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3487

GAGGVGKSA	Peptides	Inflammation/Immunology Cancer
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P1813

PSA1 (141-150) PSA-Peptide	Peptides	Cancer
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments .

HY-P10020

Alrefimotide hTERT (660–689)	Peptides	Cancer
Alrefimotide is a hTERT-derived immunogenic peptide. Alrefimotide has a sequence of ALFSVLNYERARRPGLLGASVLGLDDIHRA. Alrefimotide can be used in **cancer immunotherapy** research .

HY-P10493

NY-ESO-1 (157–165) peptide	Peptides	Others Cancer
NY-ESO-1 (157–165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157–165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157–165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy. NY-ESO-1 (157–165) peptide can be used in the study of cancer immunotherapy .